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This chapter will provide an overview of quality assurance processes to 
credential proton therapy centers for clinical trial participation. There are a 
number of credentialing audit steps, including independent output verification, 
anthropomorphic phantom audits, image guidance credentialing, knowledge 
assessments, and on-site dosimetry review. The purpose of these credentialing steps 
is to ensure consistency across proton centers participating in clinical trials, and 
well as comparability with photon centers for randomized trials. This uniformity 
ensures high quality data for measuring patient outcomes, which are pivotal at a 
time when proton therapy is being assessed for superior outcomes.
Keywords: proton therapy, quality assurance, credentialing, Imaging and Radiation 
Oncology Core, phantoms, dosimeters, image guidance, benchmarks, audits
1. Introduction
1.1 Importance of clinical trial quality assurance (QA)
Clinical trials are designed to give us confidence in a course of care. For cancer 
treatment, clinical trials have played a crucial role in the advancement of treatment 
for a variety of disease sites over the last century. As discussed in the chapter on 
clinical trials, there are a number of active protocols seeking to better understand 
the role of proton therapy within modern radiotherapy. Clinical trials have varied 
points of emphasis and radiation therapy may be an important aspect of the trial 
but not the trial endpoint. Phase II and III trials often require many participants to 
reach a statistically significant conclusion. With limited numbers of patients of var-
ious disease sites seen at an individual institution, it is common for proton therapy 
trials to be conducted among multiple institutions. When a trial includes multiple 
institutions, variability in treatment practices increases. One way to minimize 
differences across participating centers is to require QA of the trial treatment. QA 
helps minimize deviations within trials, and can improve clinical outcomes such as 
overall and progression-free survival [1–4]. This is particularly important for many 
proton therapy clinical trials, as insurance companies want to see  quantification of 
superior outcomes before agreeing to cover the cost of therapy.
1.2 National Cancer Institute (NCI) proton guidelines
In 2007, the NCI formed an ad-hoc panel of proton experts to outline guidelines 
for the use of proton therapy in clinical trials. The original guidelines included 
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recommendations about beam calibration protocol, relative biological effectiveness 
(RBE), target volumes, and clinical trial audits. The guidelines have been updated 
several times since then, most recently in 2019, to include requirements for modu-
lated pencil beam scanning delivery, robust optimization, advanced treatment 
planning algorithms, and recommendations about clinical trial credentialing [5].
2. General proton approval
2.1 Output checks
Regular remote output checks are part of clinical trial QA around the world [6]. In 
the United States (US), output checks are required on an annual basis for all proton 
beams used in the NCI’s National Clinical Trial Network (NCTN) protocols. The pur-
pose of these QA audits is to verify the output of a uniform field. Typically institutions 
use their reference calibration (International Atomic Energy Agency Technical Report 
Series 398) field for this purpose. Use of the same field year after year can catch drifts 
in output or dramatic changes that may be caused by an error in calibration.
2.2 On-site audit
In addition to the remote output check, all proton therapy centers in the US receive 
an on-site dosimetry audit as part of the baseline approval process for clinical trial 
participation. With relatively few proton centers in the US (as compared to photon 
clinics), many personnel are coming to work at new proton facilities without prior 
experience with proton therapy. On-site audits are perhaps the most crucial com-
ponent of proton approval, as they allow a deep dive into the dosimetry and clinical 
operations of a facility, and check for practice consistency across these new facilities.
The on-sites audit consists of a number of dosimetric measurements, including 
beam calibration, calibration equipment intercomparison, depth dose profiles, 
lateral beam profiles of reference and patient fields, imaging vs. radiation isocenter 
coincidence, and Hounsfield Unit (HU) – Relative Linear Stopping Power (RLSP) 
calibration. On-site audits allow for greater dosimetric accuracy and complexity 
than remote audits. Recommendations are made to the institution about how they 
can improve their clinical practice and make it more consistent with other proton 
centers on multi-institutional trials. The most common recommendation relates to 
the HU-RLSP conversion curve that institutions use to predict proton range within 
a patient [7, 8]. The curve is sensitive to errors at low densities (e.g. lung tissue) and 
variability is observed across institutions at both low and high densities. Accuracy 
of this calibration is critical to accurate proton beam modeling and by minimizing 
deviations in the calibration, treatment delivery deviations can also be mitigated.
The on-site audit also includes a review of clinical practices, covering topics like 
CT simulation and re-simulation over the course of treatment, patient immobiliza-
tion, treatment planning and robustness evaluation, and image guidance. The goal 
is to ensure consistency across institutions, in an effort to minimize deviations on 
trials. For example, if an institution is not performing any kind of rectal sparing 
technique for prostate treatment, a recommendation might be made to investigate 
and adopt a technique in order to follow standard clinical practices. The machine 
QA practices are also reviewed to ensure compliance with recommended standards 
[9–12]. The proton QA standards are relatively new, so the review of QA practices 
provides useful feedback on ways to implement different tests, benefits and 
 drawbacks of different equipment, and failure modes within the system.
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Anthropomorphic phantoms are one of the most robust options for remote 
audits of a radiotherapy modality. They encompass an end-to-end test of simula-
tion, treatment planning, setup, and delivery of radiation. Proton therapy presents 
some unique challenges for phantom tests. The plastics typically used for QA of 
photon beams are not necessarily “tissue-equivalent” in a proton beam, thus appro-
priate phantom materials need to be tested to ensure they fall on a clinical proton 
HU-RLSP curve [8].
The phantoms currently available for proton credentialing test a variety of 
different clinical requirements: conformality (brain, head and neck (H&N), 
spine), organs at risk (OAR) avoidance (H&N, prostate), motion management 
(liver, lung), heterogeneities (lung, spine), and multiple targets (liver) [13, 14]. 
Proton anthropomorphic phantom credentialing has already led to improvements 
in accuracy of treatment dose calculations for clinical trials. The lung phantom 
credentialing for the Radiation Therapy Oncology Group’s (RTOG) randomized 
proton vs. photon trial for non-small cell lung cancer (NSCLC) (RTOG 1308) found 
gross overestimates of dose when using an analytic algorithm for dose calculations 
in low-density heterogeneities [15]. The NCI has updated their proton therapy 
guidelines to require Monte Carlo or advanced algorithms for future trials with low 
density heterogeneities [5].
3.2 Image guidance
Image guidance is a crucial component of proton therapy because the beam 
range is dependent on the density of the material in its path. If you plan a field in 
soft tissue and then a bone is in the beam path at the time of treatment, you could 
entirely miss your target. Alternatively, if high density tissue is in the beam path 
at the time of planning but not at the time of treatment delivery, you risk deliver-
ing full dose to the tissue distal to the target. Most proton centers began by using 
orthogonal kV image guidance, but many now have in-room volumetric imaging 
capabilities with CT or cone-beam CT (CBCT) [16, 17].
There are many components of image guidance that are important to verify: 
image quality, geometric accuracy, imaging dose, imaging system communication, 
and safety [9–11]. Some of these components, like imaging dose and image-guided 
radiotherapy (IGRT) safety checks, are left to the institution’s physics team to 
test. Other elements are verified through clinical trial credentialing. Many proto-
cols require IGRT credentialing for both photon and proton therapy if “reduced 
margins” (typically less than 5 mm) are used. The IGRT credentialing requires 
submission of actual patient IGRT data for central review, as well as completion of a 
questionnaire outlining IGRT practices. The images are reviewed for registration to 
reference treatment planning data as well as consistency from day-to-day. The goal 
of this credentialing is to ensure consistency of IGRT processes and quality across 
institutions.
Of course, there could be accurate in-room images, but if the proton beam is not 
coincident with the IGRT isocenter, the accuracy of the beam delivery is negatively 
impacted. For this reason, the coincidence of the IGRT and proton beam isocenters 
is verified for proton therapy centers participating in clinical trials. This is done 
with a Winston-Lutz type test as part of the baseline approval process for clinical 
trial participation [18].
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3.3 Motion management
Motion management is of particular importance in proton therapy due to 
the sensitivity of the beam range to changes in tissue density [19, 20]. Several 
anthropomorphic phantoms (liver, lung) assess the end-to-end process of motion 
management, but there are some clinical trials that also require a motion manage-
ment questionnaire. This questionnaire assesses the standard clinical practices for 
assessing and accommodating target motion, such as the upper limit for motion 
magnitude, simulation practices, respiratory management system, and patient 
setup requirements. Many of these aspects are also reviewed during the on-site 
audit, so a separate motion management questionnaire for a specific clinical trial 
may not be necessary.
3.4 Knowledge assessments
A knowledge assessment asks questions about a clinical trial to ensure that 
participants have carefully reviewed the protocol and understand its requirements. 
Knowledge assessments are used for credentialing in a handful of NCTN clinical 
trials. Knowledge assessments can be useful for randomized proton vs. photon trials 
because there are intricacies of treating with two modalities, such as accounting for 
RBE, different definitions of target structures, and partnerships among multiple 
institutions. Unfortunately the knowledge assessment only captures the knowledge 
of a few personnel at a specific point in time, so it does not ensure that everyone 
involved over the course of the trial has carefully read the protocol. For this reason, 
most new NCTN proton clinical trials do not require knowledge assessments.
3.5 Benchmark cases
Benchmark cases have commonly been used for clinical trial credentialing 
[21, 22]. The objective is to have a standard sample case that all participants plan 
on. The reviewer can then assess quality of contours, beam arrangement, and target 
coverage. Often an independent dose recalculation is also performed to assess the 
accuracy of the institutions’ treatment plan dose calculations. Benchmarks can be 
a great way to identify variability across centers and offer a platform to provide 
feedback to participants for improving their practices.
In addition to planning benchmark cases, there is also an image-fusion bench-
mark case that is used for some central nervous system (CNS) trials. The bench-
mark reviews an institution’s fusion of CT and MR images. For proton therapy, this 
benchmark can be particularly useful. Proton therapy cannot be planned directly 
on MR images because the HU values from CT are required for beam range calcula-
tions, and the proton range is sensitive to anatomical changes, so proper fusion of 
MR and CT images is important for treatment delivery accuracy.
There are two challenges with benchmarks; one general and one proton-specific. 
There have been a few instances where a clinical trial required a benchmark and 
hundreds of institutions completed the benchmark, but then when it came to 
patient enrollment, only a small fraction of those initial institutions enrolled 
patients on-protocol. Reviewing benchmarks is time-intensive for the QA office and 
at times this method of up-front verification does not yield commensurate reward. 
For proton therapy specifically, the NCTN QA group does not yet have an indepen-
dent dose calculation that can be used for all proton therapy centers, so benchmarks 
can only be used as a qualitative assessment rather than a quantitative one. For these 
reasons, clinical trial QA is shifting away from standard benchmark cases.
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3.6 Pre-treatment, on-treatment and post-treatment review
In lieu of benchmark cases, many clinical trials are shifting toward pre-treatment 
or on-treatment review of actual patients enrolled in the trials. A pre-treatment 
review is the submission of the actual treatment plan for a patient intended to be 
treated on protocol. The plan is rapidly reviewed by clinical trial staff or volunteers 
and feedback is provided to the participating institution before the start of that 
patient’s treatment. Most commonly, the contours, target dose coverage, and dose 
to critical structures are reviewed. For proton therapy, the beam arrangement and 
potential sources of range uncertainty are also evaluated.
The advantage of pre-treatment review is that it can reduce the number of 
protocol deviations. If an institution receives feedback about ways to improve one 
patient’s treatment, this benefits the individual patient and can also benefit subse-
quent patients treated at the same institution. The biggest drawback of pre-treat-
ment review is the time-sensitivity of the plan review. Typically the turnaround 
for such reviews is three business days, but sometimes this is done more quickly. 
This requires that there is always personnel available to review cases, and does not 
allow for the reviewer to batch reviews at a time convenient to them. To balance the 
demands of pre-treatment review, some protocols will require pre-treatment review 
for the first few (e.g. five) patients from an individual institution. Other trials 
might place a quantitative criterion for when to require pre-treatment review; one 
trial requires pre-treatment review if the high dose goal for the target is not met. 
This is a good compromise to allow early feedback to shape an institution’s practices 
throughout the protocol.
On-treatment reviews, performed while the patient is being treated, can allow 
similar timely feedback as pre-treatment reviews. They are less time-sensitive, but 
can have a similar positive down-stream impact on subsequent patients treated by 
the same institution. Another benefit of the pre- and on-treatment reviews is they 
give the reviewers a chance to see common issues across multiple institutions, which 
can be addressed during investigator discussions during the trial and help ensure 
consistency as the trial moves forward.
Post-treatment reviews are typically performed for all plans, regardless of 
whether pre- or on-treatment reviews were performed. They assess many of the 
same criteria, as well as protocol compliance for duration of treatment time.
4. Conclusion
Independent peer review is an important component in clinical trials with radia-
tion therapy, particularly in the emerging field of proton therapy. The credentialing 
efforts required by the NCI are a paradigm for other proton clinical trials. With the 
future of proton therapy relying on results of many clinical trials, it is important to 
get the basics right. Through standard checks of consistency and comparability, we 
ensure high quality trial data for strong statistical analysis of outcomes.
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